Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Master's Award: Canada Graduate Scholarships

McMaster University

$27,000.00

Investigating pharmacological inhibition of RIPK1 as a therapeutic approach to necroptosis in PDZK1/LDLR double knockout mice on a high fat/cholesterol and cholate-enriched diet.

EF 2024-25

Résumé
Coronary heart disease, the leading cause of death world-wide, is a multifaceted condition that is influenced by various mechanisms, with atherosclerosis playing a key role. This project aims to investigate whether the pharmacological inhibition of RIPK1 with GSK’772 can protect male and female mice lacking both PDZK1 and LDLR, fed a high fat/cholesterol and cholate-enriched diet, from necroptosis, a type of programmed cell death. On this particular diet, these mice develop atherosclerotic plaques in their coronary arteries and aortic sinuses, as well as myocardial infarctions. We will examine whether necroptosis is reduced in the atherosclerotic plaques of the coronary arteries and aortic sinuses through histological analysis. Additionally, we will assess heart damage due to myocardial infarctions by staining for collagen-rich scars using histology and analyzing blood plasma levels. Using immunofluorescence staining to detect markers involved in the necroptosis pathway, such as RIP3K and MLKL, we will analyze the impact of GSK’772 on necroptosis. Furthermore, we will measure left ventricular function in their hearts using pressure-volume analysis. We will also investigate the effect of GSK’772 on cultured primary mouse and human macrophages to examine the in vitro response. This research could contribute to developing innovative strategies for cardiovascular disease management, ultimately improving public health and informing clinical practices. Funding from CGS-M will enhance my research capabilities and contribute to our further understanding of how HDL is protective, as well as to the development of new therapeutics targeting cardiovascular diseases.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
536531
Name
Lekuti Temitope R
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Investigating pharmacological inhibition of RIPK1 as a therapeutic approach to necroptosis in PDZK1/LDLR double knockout mice on a high fat/cholesterol and cholate-enriched diet.
Programtype2
Studentship Programs
Orgnameinp2
McMaster University
Cihramount2
$27,000
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Atherogenic Diet; Atherosclerosis; Cardiovascular Disease; Disease Prevention; Inflammation; Mouse Model; Necroptosis; Pharmacology; R1pk1; Sex Differences
Abstract
Coronary heart disease, the leading cause of death world-wide, is a multifaceted condition that is influenced by various mechanisms, with atherosclerosis playing a key role. This project aims to investigate whether the pharmacological inhibition of RIPK1 with GSK’772 can protect male and female mice lacking both PDZK1 and LDLR, fed a high fat/cholesterol and cholate-enriched diet, from necroptosis, a type of programmed cell death. On this particular diet, these mice develop atherosclerotic plaques in their coronary arteries and aortic sinuses, as well as myocardial infarctions. We will examine whether necroptosis is reduced in the atherosclerotic plaques of the coronary arteries and aortic sinuses through histological analysis. Additionally, we will assess heart damage due to myocardial infarctions by staining for collagen-rich scars using histology and analyzing blood plasma levels. Using immunofluorescence staining to detect markers involved in the necroptosis pathway, such as RIP3K and MLKL, we will analyze the impact of GSK’772 on necroptosis. Furthermore, we will measure left ventricular function in their hearts using pressure-volume analysis. We will also investigate the effect of GSK’772 on cultured primary mouse and human macrophages to examine the in vitro response. This research could contribute to developing innovative strategies for cardiovascular disease management, ultimately improving public health and informing clinical practices. Funding from CGS-M will enhance my research capabilities and contribute to our further understanding of how HDL is protective, as well as to the development of new therapeutics targeting cardiovascular diseases.
Competitiondate
202412
Approvedterm2
1 yr 0 mth
Pinamesdelim
Lekuti, Temitope R
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $27,000~ $0~